Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook

Earnings Call Insights: Vanda Pharmaceuticals (VNDA) Q1 2026

MANAGEMENT VIEW

* "Vanda delivered strong commercial execution in the first quarter, highlighted by 26% year-over-year growth in Fanapt sales, the groundbreaking U.S. launch of NEREUS with its pioneering direct-to-consumer platform at nereus.us and the FDA approval of BYSANTI." (Founder, President, CEO & Chairman of The Board Mihael Polymeropoulos)
* "Full year 2026 revenue guidance was raised to $240 million to $290 million, including $10 million to $30 million from newly launched NEREUS." (CEO Polymeropoulos)
* "BYSANTI, milsaperidone received FDA approval for the treatment of bipolar I disorder and schizophrenia" and "is protected by data exclusivity through February 20, 2031, and multiple patents, the latest of which expires on May 31st, 2044." (CEO Polymeropoulos)
* "The FDA accepted the biologic license application for imsidolimab in Generalized Pustular Psoriasis with a Prescription Drug User Fee Act target action date of December 12, 2026." (CEO Polymeropoulos)
* "Total revenues for the first quarter of 2026 were $51.7 million" and the sequential decline was "primarily driven by the impact of insurance plan disruptions and deductible resets that are typical in the industry at the beginning of the year." (Senior VP, CFO & Treasurer Kevin Moran)

OUTLOOK

* "Vanda is raising its full year 2026 total revenue guidance to reflect the potential contribution of newly launched NEREUS while maintaining prior ranges for Fanapt and other products." (CFO Moran)
* "Total revenues from Fanapt, HETLIOZ, PONVORY and NEREUS of between $240 million and $290 million." (CFO Moran)
* "Fanapt net product sales of between $150 million and $170 million" with the range tied to sequential prescription growth assumptions for the remainder of 2026. (CFO Moran)
* "Other net product sales of between $80 million and $90 million" assuming "a further decline of the HETLIOZ business due to generic competition" and "modest growth of the PONVORY business" tied to efforts to improve access. (CFO Moran)
* "NEREUS net product sales of between $10 million and $30 million." (CFO Moran)
* Compared with the prior quarter’s call, management changed total revenue guidance from "between $230 million and $260 million" (excluding NEREUS) to "between $240 million and $290 million" (including NEREUS) and added first-time NEREUS sales guidance. (CFO Moran, Q4 2025 vs. Q1 2026)

FINANCIAL RESULTS

* "Total revenues for the first quarter of 2026 were $51.7 million" vs. "$57.2 million for the fourth quarter of 2025." (CFO Moran)
* "Fanapt net product sales were $29.6 million" and "HETLIOZ net product sales were $15.9 million" and "PONVORY net product sales were $6.2 million" for Q1 2026. (CFO Moran)
* "Vanda recorded a net loss of $48.6 million" and "operating expenses for the first quarter of 2026 were $101.9 million," with the increase "primarily driven by higher SG&A" and "higher legal expenses." (CFO Moran)
* "Vanda's cash, cash equivalents and marketable securities... as of March 31, 2026, was $202.3 million" and the decrease included "a onetime milestone payment of $10 million made to Eli Lilly in the first quarter of 2026 for the approval of NEREUS in the U.S." (CFO Moran)

Q&A

* Olivia Brayer, Cantor Fitzgerald: asked what drives the "big range" for "$10 million to $30 million" NEREUS guidance and BYSANTI launch progress; CEO Polymeropoulos said "it is very early on the NEREUS launch" and CFO Moran said the range is "not informed by actual data" and BYSANTI availability is still planned for "the back half of the year." (CEO Polymeropoulos; CFO Moran)
* Raghuram Selvaraju, H.C. Wainwright: asked timing and expectations for the GLP-1 vomiting Phase III; CFO Moran reiterated "results by the end of 2026" and CEO Polymeropoulos said the Phase III is "of a very similar design" aiming to confirm "significant reduction in vomiting episodes" seen previously, while noting "with this short study, we will not have" adherence data. (CFO Moran; CEO Polymeropoulos)
* Selvaraju, H.C. Wainwright: asked about off-label GLP-1 use and iloperidone LAI; CEO Polymeropoulos said "we cannot promote off label" and described the LAI study as "going slowly" with Vanda planning to "engage the FDA" and potentially "modify the development plan." (CEO Polymeropoulos)
* Madison Wynne El-Saadi, B. Riley: asked if Vanda is preparing for an imsidolimab launch and what indications may be on label; CEO Polymeropoulos said Vanda’s proposed indication supports "both immediate treatment of acute flares" and "maintenance" and added, "We do not expect that we will be commercially launching right after the PDUFA date" and "hopefully, we can do that within the first half of 2027." (CEO Polymeropoulos)
* Leszek Sulewski, Truist: asked Fanapt mix, wholesaler inventory risk, BYSANTI launch priorities, MDD timing shift, and NEREUS access/pricing; CFO Moran said Vanda expects Fanapt growth to be "primarily" from bipolar, didn’t expect destocking while growth continues, and plans to prioritize "both" new starts and switches to BYSANTI; CEO Polymeropoulos said the MDD readout moved to "the first quarter of 2027" due to "better data now on recruitment speed." (CFO Moran; CEO Polymeropoulos)
* Faye (for Andrew Tsai), Jefferies: asked confidence in BYSANTI MDD success and NEREUS sales cadence; CEO Polymeropoulos said "we're quite confident" and CFO Moran said post-launch revenue should rise as "we continue to investing" in DTC promotion through the year. (CEO Polymeropoulos; CFO Moran)

SENTIMENT ANALYSIS

* Slightly negative analyst tone, with repeated probing on wide NEREUS guidance, BYSANTI monetization timing, LAI recruitment risk, and commercialization logistics (e.g., "somewhat of a big range"; "what drove the timing shift?"). (Brayer, Selvaraju, Sulewski)
* Slightly positive management tone in prepared remarks ("transformational year"; "position the company for continued growth") but more cautious/defensive in execution-specific topics ("very early"; "not informed by actual data"; LAI study "going slowly"; imsidolimab launch "some lag time"). (CEO Polymeropoulos; CFO Moran)
* Versus the prior quarter, the current call added more launch-execution caveats on NEREUS and development uncertainty on LAI, while maintaining confidence language around portfolio expansion and regulatory timelines. (CEO Polymeropoulos; CFO Moran)

QUARTER-OVER-QUARTER COMPARISON

* Guidance expanded from Q4’s "$230 million to $260 million" (Fanapt/HETLIOZ/PONVORY) to Q1’s "$240 million to $290 million" (adds NEREUS) and introduced NEREUS sales guidance of "between $10 million and $30 million." (CFO Moran)
* NEREUS moved from "actively preparing for its commercial launch" (Q4) to being "commercially available nationwide through nereus.us" (Q1), with management emphasizing the direct-to-consumer model and discounted cash-pay access. (CEO Polymeropoulos)
* BYSANTI moved from "under FDA review" with a February 2026 PDUFA (Q4) to "received FDA approval" (Q1), with commercialization still framed around back-half 2026 availability. (CEO Polymeropoulos; CFO Moran)
* The expected timing for BYSANTI MDD data shifted from "expected by end of the year" (Q4) to "results expected in Q1 2027" (Q1). (CEO Polymeropoulos)

RISKS AND CONCERNS

* "HETLIOZ net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S." (CFO Moran)
* Cash usage was highlighted via the Q1 cash decline, including "a onetime milestone payment of $10 million" and management reiterated, "it is likely that Vanda's 2026 cash burn will be greater than the cash burn in 2025." (CFO Moran)
* For NEREUS, management emphasized uncertainty early in launch: the $10 million to $30 million range is "not informed by experience" and payer coverage will be "a process that plays out over coming quarters and years." (CEO Polymeropoulos; CFO Moran)
* For iloperidone LAI, CEO Polymeropoulos said the study "is going slowly" with concerns about recruitment and placebo relapse rates, and Vanda may "modify the development plan" after FDA discussion. (CEO Polymeropoulos)

FINAL TAKEAWAY

Management framed Q1 2026 as a launch-and-franchise expansion period, pointing to raised 2026 revenue guidance of $240 million to $290 million that now includes a first-time NEREUS sales outlook of $10 million to $30 million, while reiterating Fanapt’s growth strategy and acknowledging pressures from HETLIOZ generic competition. Executives repeatedly emphasized that NEREUS is in early launch with guidance based on modeling rather than experience, BYSANTI is approved but expected to be commercially available in the back half of 2026, and imsidolimab’s BLA has a December 12, 2026 target action date with a commercial launch likely lagging into 2027.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/vnda/earnings/transcripts]

MORE ON VANDA PHARMACEUTICALS

* Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4900059-vanda-pharmaceuticals-inc-vnda-q1-2026-earnings-call-transcript]
* Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy [https://seekingalpha.com/article/4873553-vanda-pharmaceuticals-soaring-on-bysanti-approval-but-you-shouldnt-feel-dizzy]
* Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week [https://seekingalpha.com/article/4872007-vanda-pharma-high-risk-heavily-discounted-stock-ahead-pdufa-this-week]
* Vanda Pharmaceuticals GAAP EPS of -$0.82 misses by $0.13, revenue of $51.7M misses by $1.2M [https://seekingalpha.com/news/4587497-vanda-pharmaceuticals-gaap-eps-of-0_82-misses-by-0_13-revenue-of-51_7m-misses-by-1_2m]
* Vanda Pharmaceuticals Q1 Earnings Preview [https://seekingalpha.com/news/4585973-vanda-pharmaceuticals-q1-earnings-preview]